TME Pharma NV (XPAR:ALTME) Stock Based Compensation : €0.31 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Stock Based Compensation?

TME Pharma NV's Stock Based Compensation for the six months ended in Dec. 2024 was €0.10 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was €0.31 Mil.

TME Pharma NV Stock Based Compensation Historical Data

The historical data trend for TME Pharma NV's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Stock Based Compensation Chart

TME Pharma NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

0.16

0.48

0.59

0.40

0.31

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Stock Based Compensation	Get a 7-Day Free Trial															0.20	0.20	0.20	0.21	0.10

TME Pharma NV Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.31 Mil.

TME Pharma NV Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

0N6A:Germany

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines